Singapore, April 22 -- As part of its commitment to advance healthcare innovation, the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company.

As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the emirate.

These agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering t...